Kelly Morgan, MS, CGC, on Pre- and Post-Test Online Education for the Ashkenazi Jewish BRCA Mutation

Video

The MSK expert discussed what pre- and post-test online education consists of in testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers.

In an interview with CancerNetwork, Kelly Morgan, MS, CGC, a genetic counselor at Memorial Sloan Kettering Cancer Center, what pre- and post-test online education consists of in testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system.

Transcript:

This was all through self-motivated enrollment, if you Well, you know, the study was community outreach based, essentially, participant would go online to a portal where they would receive chat bot based education. And that would consist of both text and videos that would cover the information that one might need to make an informed decision about whether or not genetic testing was right for them. And then as an added component, what it meant to be a study participant. So through the combination of the video and the conversational chat bot, participants would learn what they may need to know to choose to participate and then you know, make a decision and move forward and it was all something they could do online from home on their own time, as opposed to say in a clinicians office, but it still had that medical component of the core of the information they may might need.

Yeah, so it was during registration that participants would have the chance to select whether they prefer to receive results from their primary care provider or a study genetic counselor. So if they were to choose a primary care provider, then we as a study team would reach out to the primary care provider share information about what would be involved in the study and disclosing genetic test results to their patients. And they could choose whether or not they wanted to participate. And so for primary care providers who opted in to the study, they would then be responsible for sharing results with their patients and then as a study team, we would also provide support and guidance if any doctors had questions or wanted more information.

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content